Teniposide (VM-26) is an epipodophyllotoxin anticancer drug, widely used as a single agent or in combination for the treatment of children with different malignancies (acute lymphoblastic leukemia, lymphomas, neuroblastoma). It is a phase-specific cytotoxic agent inducing premitotic block in the cell cycle by stabilizing the DNA-topoisomerase II complex. The dose-limiting toxicity of the drug is myelosuppression.
Acute Lymphoblastic Leukemia Plasma Protein Binding Total Protein Concentration Free Fraction Cytosine Arabinoside
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Sinkule JA, Stewart CF, Crom WR; Melton ET, Dahl GV et al: Teniposide (VM-26) disposition in children with leukemia. Cancer Res 1984 44: 1235–1237PubMedGoogle Scholar
Rodman JH, Abromowith M, Sinkule JA, et al.: Clinical pharmacodynamics of continuous infusion teniposide: Systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 1987. 5: 1007–14PubMedGoogle Scholar
Stewart CF, Pieper JA, Arbuck SG et al.: Altered protein binding of etoposide in patients with cancer. Clin Pharmacol Ther 1989. 45 (1) 49–55PubMedCrossRefGoogle Scholar
Huang J: Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis. J Pharm Sci 1983. 72: 1368–1369PubMedCrossRefGoogle Scholar